CÁNCER DE PRÓSTATA ON GOING EVALUACION DE ENSAYOS

ON GOING

1. CÁNCER DE PRÓSTATA ON GOING

2. Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol

3. INDICATE: : Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post- prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191

4. Journal of Clinical Oncology. Volume 42, Number 4_suppl

5. Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase 2 Multi-arm Biomarker-Based Study

6. CYCLONE 3 (NCT05288166) evaluating the addition of abemaciclib to abiraterone+prednisone (AP) in pts with high-risk mHSPC

7. CAPItello-281 AKTi

8. TALAPRO 2 ( mCRPC )  3: Poly (ADP- ribose ) polymerase inhibitors in combination with androgen -receptor signaling inhibitors are a promising therapeutic option for patients with metastatic castration -sensitive prostate cancer ( mCSPC ) and homologous recombination repair (HRR) gene alterations

9. PSMAddition : delivers beta-radiation (B-) which ablates (destroys) the cancer cells. The B- radiation travels a few millimeters from where it locates.

10. Apalutamide and Stereotactic Body Radiation Therapy for Low-Burden, Metastatic, Hormone-Sensitive Prostate Cancer: A Randomized Trial (PERSIAN)

11. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre , phase II randomised controlled trial

12. GRACIAS